Predictors of the Effect of Tolvaptan on the Prognosis of Cirrhosis

Predictors of the Effect of Tolvaptan on the Prognosis of Cirrhosis

Objective Tolvaptan was first approved for use for cirrhosis in Japan in September 2013. The aim of the study was to examine the effect of tolvaptan, a vasopressin V2 receptor antagonist, on the prognosis of cirrhosis.

Bibliographic Details
Main Authors: Iwamoto, Takuya, Maeda, Masaki, Hisanaga, Takuro, Saeki, Issei, Fujisawa, Koichi, Matsumoto, Toshihiko, Hidaka, Isao, Ishikawa, Tsuyoshi, Takami, Taro, Sakaida, Isao
Format: Online
Language:English
Published: The Japanese Society of Internal Medicine 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109555/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109555/

Similar Items